Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 1
1963 1
1964 1
1965 3
1966 2
1968 3
1969 6
1970 2
1971 1
1972 5
1973 7
1974 2
1975 2
1976 1
1977 1
1978 5
1979 3
1980 2
1981 5
1982 6
1983 1
1984 7
1985 4
1986 7
1987 3
1989 1
1990 2
1991 2
1992 1
1993 2
1994 4
1995 6
1996 2
1997 2
1998 2
2000 6
2001 4
2002 2
2006 4
2007 2
2008 3
2009 1
2010 1
2012 4
2013 9
2014 11
2015 11
2016 14
2017 23
2018 26
2019 24
2020 28
2021 27
2022 27
Text availability
Article attribute
Article type
Publication date

Search Results

305 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Akamatsu H, et al. Among authors: fujimoto d. JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. JAMA Oncol. 2021. PMID: 33410885 Free PMC article. Clinical Trial.
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS. Torlakovic E, et al. Among authors: fujimoto d. Mod Pathol. 2020 Jan;33(1):4-17. doi: 10.1038/s41379-019-0327-4. Epub 2019 Aug 5. Mod Pathol. 2020. PMID: 31383961 Free PMC article. Review.
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Fujimoto D, et al. Eur J Cancer. 2021 Jun;150:63-72. doi: 10.1016/j.ejca.2021.03.016. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892408
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Hayashi H, et al. Among authors: fujimoto d. Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi: 10.1158/1078-0432.CCR-21-3194. Clin Cancer Res. 2022. PMID: 34921023 Clinical Trial.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: fujimoto d. Chest. 2022 Jun 1:S0012-3692(22)01068-6. doi: 10.1016/j.chest.2022.05.035. Online ahead of print. Chest. 2022. PMID: 35661746
Recurrence risk factors in stage IA grade 1 endometrial cancer.
Nwachukwu C, Baskovic M, Von Eyben R, Fujimoto D, Giaretta S, English D, Kidd E. Nwachukwu C, et al. Among authors: fujimoto d. J Gynecol Oncol. 2021 Mar;32(2):e22. doi: 10.3802/jgo.2021.32.e22. Epub 2021 Jan 8. J Gynecol Oncol. 2021. PMID: 33470064 Free PMC article.
305 results